Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$117.52
▼ $0.99 (-0.8%)
Market data updated: 09/17 07:21 PM
Fundamentals updated: 09/17/2026
News analyzed: 09/17/2026
Market Cap
$2.19B
Day Range
$117.01 - $118.76
52-Week Range
$87.95 - $124.44
Beta
—
Next Earnings
02.11.2026
ADUS is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+9.0% (1Y)
Strengths: 15/31 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 23.2%
Growth
Biggest negative driver
Calmar Ratio (return vs. drawdown)
Calmar: 0.35 (3y annualized return 12.1% / max drawdown 34.9%)
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
63
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
68
Quality
63
Value
50
Momentum
61
Risk
54
Sentiment
86
Fundamental
62
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Addus HomeCare Corporation has centered on its **Q2 2026 earnings performance**, where it reported revenue meeting expectations alongside a surprise earnings per share beat, sparking investor speculation about its stock valuation. Analysts debated whether the share price—despite a slight short-term dip—reflects its fundamentals fairly, with some suggesting undervaluation based on historical returns and intrinsic value estimates. The company’s participation in the **2026 Jefferies Healthcare Services Conference** also drew attention, while broader market comparisons and growth stock discussions framed its position in the healthcare services sector.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Addus HomeCare Corporation. News trend score: 86. Reason: 10 of the last 20 articles are positive, versus 4 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
18
🎯 Conviction (vs. Emotion)
42
Psychology
21
Fundamentals
62
Technical
61
Valuation
50
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price rise has far outpaced the actual improvement in fundamental data.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
+25%
Market Narrative
61
Fundamental Reality
42
Narrative Gap
+19
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
ADUS’s psychology is fragmented, with **anchoring** dominating (36) due to proximity to resistance, while **euphoria** (19) reflects valuation above fair value. The **narrative-reality gap** (8) hints at a disconnect between optimistic pricing and flat momentum. **Overconfidence** (8) may linger if traders overlook lagging price performance relative to fundamentals. The key question: will traders anchor to resistance or pivot if momentum shifts?
Updated: 09/08/2026, 10:50 PM
👥 What the crowd believes
"Addus HomeCare Q2 results showed revenue in line with expectations alongside an earnings per share beat (article 7)."
"Addus HomeCare stock has delivered a 34.6% gain over the past three years, suggesting undervaluation (article 9)."
"Addus HomeCare reviewed alongside peers in senior health/home health/hospice sector (article 11)."
📈 4D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Peter Lynch — 79/100
🔴 Weakest match
Jack Schwager — 18/100
🗣️ Why do they disagree?
This stock sparks a sharp divide between growth-focused and value/cycle-sensitive methodologies. Peter Lynch and Walter Bagehot both score it highly (79), with Lynch seeing untapped upside in its growth potential and Bagehot praising its resilience through liquidity—both aligning on its strength in turbulent conditions. Meanwhile, value-oriented investors like Benjamin Graham (42) and Jack Schwager (22) dismiss it outright, with Schwager’s mechanical approach rejecting any setup and Graham’s strict criteria failing to find defensive value. The middle ground is occupied by mixed signals: Howard Marks (61) and Thorstein Veblen (60) note potential overvaluation or profit uncertainty, while Morgan Housel (48) acknowledges it’s holdable but not effortless—suggesting it’s neither a slam dunk nor a red flag, but a stock where conviction matters.
Peter Lynch
One Up on Wall Street (1989)
🟢 79
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 79
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 73
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟢 65
Reasonable capital-preservation profile
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 62
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 60
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 57
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟡 51
Mid-cycle — no strong signal either way
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 51
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 50
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 49
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 48
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 43
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 40
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 31
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 18
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Based on the last 279 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (5 bullish · 3 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
32.5%
Operating Margin
9.7%
Net Margin
6.7%
EBITDA Margin
10.9%
ROE
8.8%
ROA
6.7%
ROIC
—
EPS
$5.31
Cash
—
Total Debt
$120.96M
Current Ratio
1.80
Debt/Equity
0.11
How is Fair Value calculated? →
Current Price
$117.52
Estimated Fair Value (DCF)
$109.49
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-6.8%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
14.5%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 14.5% | $118.86M | $109.05M |
| 2 | 11.5% | $132.55M | $111.57M |
| 3 | 8.5% | $143.84M | $111.07M |
| 4 | 5.5% | $151.76M | $107.51M |
| 5 | 2.5% | $155.55M | $101.10M |
Base FCF (last actual year)
$103.79M
Terminal Value
$2.45B
Present Value of Terminal Value
$1.59B
Enterprise Value
$2.13B
Net Debt
$120.96M
Equity Value
$2.01B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$59.01
Tangible Book Value per Share (Tangible NAV)
-$0.75
Sentiment based on basic keywords (not AI) — 10 positive, 6 neutral, 4 negative out of the last 20 articles.
Yahoo · 16.9.2026
Yahoo · 15.9.2026
Yahoo · 14.9.2026
Yahoo · 14.9.2026
Yahoo · 14.9.2026
Yahoo · 14.9.2026
Yahoo · 14.9.2026
Benzinga · 14.9.2026
Benzinga · 14.9.2026
Yahoo · 12.9.2026
StockStory · 12.9.2026
Yahoo · 11.9.2026
Zacks · 11.9.2026
Yahoo · 8.9.2026
Business Wire · 8.9.2026
ChartMill · 5.9.2026
Yahoo · 4.9.2026
Zacks · 4.9.2026
Yahoo · 3.9.2026
StockStory · 3.9.2026
Addus HomeCare Corporation (ADUS) currently has a StockIQ AI score of 63/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
ADUS currently scores 63/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, ADUS's estimated fair value is $109.49, which is 6.8% below the current price of $117.52. This is one valuation model among several signals in the fair-value category, not a price target.
ADUS's technical score is 61/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 23.2%; Earnings per share (EPS) growth: 23.4%; Net income growth: 30.3%.
Based on the real signals StockIQ computed: Calmar: 0.35 (3y annualized return 12.1% / max drawdown 34.9%); Free cash flow growth: -6.0%; MACD histogram is negative — falling momentum.
StockIQ has no recorded dividend payment history for ADUS.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 11 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Dixon Heather Brianne | Open Market Sale | 22.6.2026 | 288 | -288 | $93.77 |
| Dixon Heather Brianne | Open Market Sale | 22.6.2026 | 44,371 | -288 | $93.77 |
| Weaver Susan T | Grant/Award from Employer | 10.6.2026 | 1,449 | +1,449 | — |
| Gordon Darin J. | Grant/Award from Employer | 10.6.2026 | 1,449 | +1,449 | — |
| RUSH JEAN | Grant/Award from Employer | 10.6.2026 | 1,449 | +1,449 | — |
| Lopez Esteban | Grant/Award from Employer | 10.6.2026 | 1,449 | +1,449 | — |
| Hill-Milbourne Veronica | Grant/Award from Employer | 10.6.2026 | 1,449 | +1,449 | — |
| FIRST MARK L | Grant/Award from Employer | 10.6.2026 | 1,449 | +1,449 | — |
| EARLEY MICHAEL | Grant/Award from Employer | 10.6.2026 | 1,449 | +1,449 | — |
| FIRST MARK L | Grant/Award from Employer | 10.6.2026 | 15,070 | +1,449 | — |
| EARLEY MICHAEL | Grant/Award from Employer | 10.6.2026 | 13,400 | +1,449 | — |
| Gordon Darin J. | Grant/Award from Employer | 10.6.2026 | 14,244 | +1,449 | — |
| Weaver Susan T | Grant/Award from Employer | 10.6.2026 | 13,744 | +1,449 | — |
| RUSH JEAN | Grant/Award from Employer | 10.6.2026 | 10,670 | +1,449 | — |
| Lopez Esteban | Grant/Award from Employer | 10.6.2026 | 4,649 | +1,449 | — |
| Hill-Milbourne Veronica | Grant/Award from Employer | 10.6.2026 | 6,516 | +1,449 | — |
| Lopez Esteban | Open Market Sale | 21.5.2026 | 250 | -250 | $93.00 |
| Lopez Esteban | Open Market Sale | 21.5.2026 | 3,200 | -250 | $93.00 |
| Lopez Esteban | Open Market Sale | 19.5.2026 | 250 | -250 | $93.00 |
| Lopez Esteban | Open Market Sale | 19.5.2026 | 3,450 | -250 | $93.00 |
| BLESSING CLIFF DONALD | Open Market Sale | 21.4.2026 | 178 | -178 | $93.61 |
| BLESSING CLIFF DONALD | Open Market Sale | 21.4.2026 | 12,183 | -178 | $93.61 |
| RAINES MONICA | Open Market Sale | 2.3.2026 | 224 | -224 | $102.15 |
| RAINES MONICA | Open Market Sale | 2.3.2026 | 13,577 | -224 | $102.15 |
| RAINES MONICA | Open Market Sale | 25.2.2026 | 219 | -219 | $105.36 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
895,318 shares short as of 2026-08-31 · vs. 1,205,635 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
77.1% of trading volume this week was short selling, vs. 79.4% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology